These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19157069)

  • 1. High-throughput screening for analysis of in vitro toxicity.
    Schoonen WG; Westerink WM; Horbach GJ
    EXS; 2009; 99():401-52. PubMed ID: 19157069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Vitotox and RadarScreen assays for the rapid assessment of genotoxicity in the early research phase of drug development.
    Westerink WM; Stevenson JC; Lauwers A; Griffioen G; Horbach GJ; Schoonen WG
    Mutat Res; 2009 May; 676(1-2):113-30. PubMed ID: 19393335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicogenomics in drug discovery and development -- making an impact.
    Wills Q; Mitchell C
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():33-7. PubMed ID: 19807202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of toxicogenomics in the development of safe, efficacious and novel anti-microbial therapies.
    Sabir JS; Abu-Zinadah OA; Bora RS; Ahmed MM; Saini KS
    Infect Disord Drug Targets; 2013 Jun; 13(3):206-14. PubMed ID: 24087896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of RAD51C, Cystatin A, p53 and Nrf2 luciferase-reporter assays in metabolically competent HepG2 cells for the assessment of mechanism-based genotoxicity and of oxidative stress in the early research phase of drug development.
    Westerink WM; Stevenson JC; Horbach GJ; Schoonen WG
    Mutat Res; 2010 Feb; 696(1):21-40. PubMed ID: 20006733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iconix Biosciences, Inc.
    Fielden MR; Halbert DN
    Pharmacogenomics; 2007 Apr; 8(4):401-5. PubMed ID: 17391077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Origin and evolution of high throughput screening.
    Pereira DA; Williams JA
    Br J Pharmacol; 2007 Sep; 152(1):53-61. PubMed ID: 17603542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current in vitro high throughput screening approaches to assess nuclear receptor activation.
    Raucy JL; Lasker JM
    Curr Drug Metab; 2010 Nov; 11(9):806-14. PubMed ID: 21189134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies.
    Donato MT; Gómez-Lechón MJ; Tolosa L
    Expert Opin Drug Discov; 2017 Feb; 12(2):201-211. PubMed ID: 27936962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High throughput screening: early successes indicate a promising future.
    Fox S; Wang H; Sopchak L; Khoury R
    J Biomol Screen; 2001 Jun; 6(3):137-40. PubMed ID: 11689109
    [No Abstract]   [Full Text] [Related]  

  • 11. A pharmaceutical company user's perspective on the potential of high content screening in drug discovery.
    Hoffman AF; Garippa RJ
    Methods Mol Biol; 2007; 356():19-31. PubMed ID: 16988392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop.
    Kirkland D; Pfuhler S; Tweats D; Aardema M; Corvi R; Darroudi F; Elhajouji A; Glatt H; Hastwell P; Hayashi M; Kasper P; Kirchner S; Lynch A; Marzin D; Maurici D; Meunier JR; Müller L; Nohynek G; Parry J; Parry E; Thybaud V; Tice R; van Benthem J; Vanparys P; White P
    Mutat Res; 2007 Mar; 628(1):31-55. PubMed ID: 17293159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gentronix.
    McCulloch P
    Pharmacogenomics; 2004 Apr; 5(3):337-40. PubMed ID: 15102548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective.
    Rodrigues AD
    Pharm Res; 1997 Nov; 14(11):1504-10. PubMed ID: 9434267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The state-of-the-art in predictive toxicogenomics.
    Fielden MR; Kolaja KL
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):84-91. PubMed ID: 16445120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a higher throughput screening approach to genotoxicity testing using the GADD45a-GFP GreenScreen HC assay.
    Knight AW; Birrell L; Walmsley RM
    J Biomol Screen; 2009 Jan; 14(1):16-30. PubMed ID: 19171918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.
    Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J
    Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SimuGen Ltd: reliable, early prediction of drug toxicity with toxicogenomics, human cell culture and computational models.
    Wills Q
    Pharmacogenomics; 2007 Aug; 8(8):1081-4. PubMed ID: 17716240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods.
    Waters MD; Jackson M; Lea I
    Mutat Res; 2010 Dec; 705(3):184-200. PubMed ID: 20399889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput screening: update on practices and success.
    Fox S; Farr-Jones S; Sopchak L; Boggs A; Nicely HW; Khoury R; Biros M
    J Biomol Screen; 2006 Oct; 11(7):864-9. PubMed ID: 16973922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.